RTI Surgical Inc (NASDAQ:RTIX) has earned a consensus broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating.
Brokers have set a 12 month consensus price target of $5.00 for the company and are predicting that the company will post $0.02 EPS for the current quarter, according to Zacks. Zacks has also assigned RTI Surgical an industry rank of 102 out of 255 based on the ratings given to its competitors.
Several analysts recently commented on RTIX shares. BidaskClub upgraded RTI Surgical from a “sell” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research upgraded RTI Surgical from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a report on Tuesday, August 7th. Finally, ValuEngine raised RTI Surgical from a “hold” rating to a “buy” rating in a research note on Monday, July 2nd.
RTIX stock traded down $0.05 during trading on Wednesday, hitting $4.55. The company had a trading volume of 600 shares, compared to its average volume of 135,983. RTI Surgical has a one year low of $3.85 and a one year high of $5.10. The stock has a market capitalization of $288.37 million, a PE ratio of 91.00 and a beta of 1.44. The company has a debt-to-equity ratio of 0.30, a current ratio of 3.86 and a quick ratio of 1.55.
RTI Surgical (NASDAQ:RTIX) last announced its earnings results on Thursday, August 2nd. The medical equipment provider reported $0.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.02. RTI Surgical had a return on equity of 3.04% and a net margin of 1.23%. The business had revenue of $70.69 million for the quarter, compared to analysts’ expectations of $70.09 million. research analysts expect that RTI Surgical will post 0.11 earnings per share for the current year.
RTI Surgical Company Profile
RTI Surgical, Inc, together with its subsidiaries, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It processes donated human musculoskeletal and other tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by using its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes.
Read More: What is Compound Annual Growth Rate (CAGR)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RTI Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical and related companies with MarketBeat.com's FREE daily email newsletter.